#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2246	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2594	257.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1941	1941	T	307	T	269	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2246	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2594	257.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1675	1675	C	336	C	276	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3550	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3875	273.9	0	.	n	.	0	A9G	SNP	9	9	A	496	496	G	316	G	269	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3550	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3875	273.9	0	.	n	.	0	T695C	SNP	695	695	T	1182	1182	C	266	C	217	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3550	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3875	273.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2458	2458	C	357	C	295	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3550	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3875	273.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3084	3084	T	300	T	259	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3550	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3875	273.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2532	2532	A	373	A,T	307,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	418	folP	855	855	99.77	folP.l15.c4.ctg.1	1914	65.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1212	1214	AGC	90;89;89	A,C;G;C	72,1;76;76	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	768	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3891	59.2	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1247	1249	ATA	80;80;80	A;T;A	69;69;68	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	768	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3891	59.2	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1268	1270	ATA	81;81;80	A;T;A	68;68;69	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	768	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3891	59.2	1	SNP	p	S91F	0	.	.	271	273	TCC	791	793	TCC	61;61;61	T;C;C	47;49;50	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	768	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3891	59.2	1	SNP	p	D95G	0	.	.	283	285	GAC	803	805	GAC	59;60;60	G;A,T;C	49;48,1;51	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	768	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3891	59.2	1	SNP	p	D95N	0	.	.	283	285	GAC	803	805	GAC	59;60;60	G;A,T;C	49;48,1;51	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	328	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1813	54.1	0	.	p	.	0	P191fs	FSHIFT	571	571	C	1145	1145	C	84	C,G	67,1	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	328	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1813	54.1	1	SNP	p	G45D	0	.	.	133	135	GGC	706	708	GGC	82;82;81	G;G;C	75;74;74	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	220	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1424	46.4	0	.	n	.	0	.206T	INS	206	206	T	819	819	T	80	T	64	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1790	1792	GCC	79;79;79	G;C;C	67;63;68	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1832	1834	GCA	74;74;74	G,T;C;A	60,1;64;63	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	1	SNP	p	D86N	0	.	.	256	258	GAC	785	787	GAC	89;90;90	G;A;C	80;78;76	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	1	SNP	p	S87I	0	.	.	259	261	AGT	788	790	AGT	90;90;90	A,C;G;T,G	76,1;80;81,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	1	SNP	p	S87R	0	.	.	259	261	AGT	788	790	AGT	90;90;90	A,C;G;T,G	76,1;80;81,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	1	SNP	p	S87W	0	.	.	259	261	AGT	788	790	AGT	90;90;90	A,C;G;T,G	76,1;80;81,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	716	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3368	63.8	1	SNP	p	S88P	0	.	.	262	264	TCC	791	793	TCC	90;90;90	T;C;C	79;81;78	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	654	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3170	61.6	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1816	1818	GGT	77;75;74	G;G,A;T	61;59,1;58	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1471	1473	GCA	85;85;85	G;C,A;A	73;72,2;75	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1474	1476	ATC	85;85;85	A;T,C;C	74;72,1;75	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1486	1488	GTG	87;87;87	G;T;G	75;75;72	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1486	1488	GTG	87;87;87	G;T;G	75;75;72	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1990	1992	ACC	74;73;73	A;C;C	62;66;67	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2044	2046	GCG	70;70;70	G,A,T;C,A;G	55,1,1;53,1;53	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2044	2046	GCG	70;70;70	G,A,T;C,A;G	55,1,1;53,1;53	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2167	2169	GGT	75;75;74	G;G;T,C,G	67;66;65,1,1	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2176	2178	GGC	73;73;71	G;G;C	65;63;63	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	602	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2700	66.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2194	2196	CCG	74;74;74	C,A,G;C;G	60,1,1;62;65	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	770	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3587	64.3	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1919	1921	CTG	61;61;61	C;T;G,T	51;55;53,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	378	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2107	53.6	0	.	p	.	0	S22G	NONSYN	64	66	AGC	549	551	GGC	63;63;63	G,T;G;C	56,1;54;56	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	378	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2107	53.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	731	731	C	63	C	52	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	T18M	NONSYN	52	54	ACG	526	528	ATG	94;94;95	A;T;G	76;77;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	616	618	GGA	96;97;97	G,T;G,A;A	78,1;77,1;80	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	V75I	NONSYN	223	225	GTT	697	699	ATT	84;84;84	A,C;T;T	71,1;71;70	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	739	741	AGC	81;80;81	A,C;G;C	68,1;65;67	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	V98I	NONSYN	292	294	GTC	766	768	ATC	78;77;77	A;T;C	63;63;63	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	831	832	CG	74;73	C;G	66;64	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	834	836	CAG	73;73;74	C;A;G	65;63;64	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	838	840	AAA	74;74;71	A;A;A,T	64;67;62,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	865	867	TAT	72;72;72	T;A,T;T,G	59;61,1;62,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	N134K	NONSYN	400	402	AAT	874	876	AAG	68;69;69	A;A;G	61;59;63	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	V135F	NONSYN	403	405	GTG	877	879	TTT	69;69;69	T;T,G;T	63;61,2;60	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	G140K	NONSYN	418	420	GGA	892	894	AAA	69;69;69	A;A;A	61;61;62	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	901	903	GAA	69;69;69	G;A;A	61;62;62	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	925	927	GCA	67;67;68	G;C;A	56;56;58	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1111	1113	TCA	82;83;83	T;C;A	72;71;71	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1231	1233	CAA	91;89;89	C;A;A	82;81;79	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	.	INDELS	760	762	ACA	1235	1239	ATCAA	91;91;90;90;90	A;T;C;A;A	80;78;78;79;82	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	.	INDELS	763	764	TG	1242	1244	AGT	91;91;91	A;G;T	82;80;80	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1249	1251	GAT	93;93;94	G;A,T,G;T	83;79,1,1;82	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1285	1287	AGC	102;102;104	A;G;C	89;87;87	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1357	1359	AGT	120;120;120	A;G,T;T	91;91,1;92	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1363	1365	GAC	119;119;119	G;A;C	89;91;89	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1366	1368	TAC	119;119;122	T,G;A;C	87,1;85;91	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	1	SNP	p	G120K	1	.	.	358	360	AAG	831	833	CGG	74;73;73	C;G;G,A	66;64;65,1	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	1	SNP	p	A121D	1	.	.	361	363	GAC	834	837	CGC	73;74;74	C;G;C,A	65;64;63,2	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	444	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2196	60.1	1	SNP	p	D121N	0	.	.	361	363	GAC	834	837	CGC	73;74;74	C;G;C,A	65;64;63,2	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	1600	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5197	92.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2174	2176	CAT	98;97;96	C;A;T	83;80;79	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	206	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1474	41.7	1	SNP	p	V57M	1	.	.	169	171	ATG	725	727	ATG	84;84;85	A;T;G	66;68;67	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
